Clinical Trials Using Anti-CD20/CD3 Monoclonal Antibody REGN1979

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CD20/CD3 Monoclonal Antibody REGN1979. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies

    This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
    Location: 9 locations

  • Study of REGN2810 and REGN1979 in Patients With Lymphoma

    This is an open-label, multicenter, dose escalation study of REGN2810 and REGN1979 in patients with lymphoma. The study treatment period will be from 6 to 12 months, depending on how an individual patient responds to treatment. The follow-up period will be 6 months for all patients.
    Location: 4 locations

  • Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma

    The primary objective of this study is to assess the anti-tumor activity of single agent REGN1979, as measured by objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) by independent central review, in patients with follicular lymphoma (FL) that has relapsed or is refractory to at least 2 prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent. The secondary objectives in this study are: - To assess the anti-tumor activity of single agent REGN1979 in patients with relapsed or refractory FL, as measured by: - ORR according to the Lugano Classification (Cheson, 2014) as assessed by local investigator evaluation - Complete response (CR) rate according to the Lugano Classification as assessed by independent central review and local investigator evaluation - Progression-free survival (PFS) according to Lugano Classification as assessed by independent central review and local investigator evaluation - Overall survival (OS) - Duration of response (DOR) according to the Lugano Classification as assessed by independent central review and local investigator evaluation - Disease control rate (DCR) according to the Lugano Classification as assessed by independent central review and local investigator evaluation - Duration of disease control (DDC) according to the Lugano Classification as assessed by independent central review and local investigator evaluation - To evaluate the safety and tolerability of REGN1979 - To assess the pharmacokinetics (PK) of REGN1979 - To assess the immunogenicity of REGN1979 - To assess the effect of REGN1979 on quality of life as measured by the validated instruments European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L)
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio